PBLA Historical PE Ratio image   This PBLA PE ratio history page last updated 1/18/2023
PBLA PE History Chart
PeriodPriceGAAPTTMPE
Q3 2022
11/10/2022
4.44-8.40-90.00NA
Q2 2022
8/15/2022
47.60-60.40-88.00NA
Q1 2022
5/12/2022
64.28-10.80-36.40NA
Q4 2021
3/24/2022
84.40-10.40-34.80NA
Q3 2021
11/10/2021
80.80-6.40-28.00NA
Q2 2021
8/11/2021
96.00-8.80-30.00NA
Q1 2021
5/12/2021
160.00-9.20NANA
Q4 2020
3/26/2021
166.00-3.60NANA
Q3 2020
11/12/2020
134.00-8.40NANA
PBLA Historical PE Ratio Chart
PeriodPriceGAAPAnnualizedPE
Q3 2022
11/10/2022
4.44-8.40-33.60NA
Q2 2022
8/15/2022
47.60-60.40-241.60NA
Q1 2022
5/12/2022
64.28-10.80-43.20NA
Q4 2021
3/24/2022
84.40-10.40-41.60NA
Q3 2021
11/10/2021
80.80-6.40-25.60NA
Q2 2021
8/11/2021
96.00-8.80-35.20NA
Q1 2021
5/12/2021
160.00-9.20-36.80NA
Q4 2020
3/26/2021
166.00-3.60-14.40NA
Q3 2020
11/12/2020
134.00-8.40-33.60NA
Quotes delayed 20 minutes

Email EnvelopeFree PBLA Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks
10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
Panbela Therapeutics (PBLA) is categorized under the Healthcare sector; to help you further research PE history across stocks, below are some other companies in the same sector:

PBYI PE Ratio History
PCRX PE Ratio History
PCSA PE Ratio History
PCVX PE Ratio History
PDCO PE Ratio History
PDEX PE Ratio History
PDSB PE Ratio History
PEN PE Ratio History
PEPG PE Ratio History
PETV PE Ratio History
On this page we presented the PBLA PE Ratio History information for Panbela Therapeutics' stock. The average PBLA PE ratio history based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is NA. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average PBLA PE ratio history based on this TTM earnings result method is NA. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this PBLA PE ratio history result, against the recent PE: when this page was posted on 1/17/2023, the most recent closing price for PBLA had been 3.28, and the most recent quarterly earnings result, annualized, was NA. Meanwhile, the most recent TTM earnings summed to NA.

For self directed investors doing their due diligence on PBLA or any other given stock, valuation analysis for PBLA can greatly benefit from studying the past earnings and resulting PE ratio history calculations. This type of study can help inform an analysis as to whether the earnings trajectory over time and current versus historical average PE ratios justify the current stock market value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Panbela Therapeutics PE ratio history — or the PE history for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for next earnings dates and also historical earnings surprises history for PBLA. Thanks for visiting, and the next time you need to research PBLA PE Ratio History or the PE ratio history for another stock, we hope our site will come to mind as your go-to PE ratio history research resource of choice.

Recommended: Top Ten Hedge Funds Holding FNGZ, Institutional Holders of Target, Funds Holding EVRY.

 

PBLA PE Ratio History | www.HistoricalPERatio.com | Copyright © 2020 - 2023, All Rights Reserved

Nothing in HistoricalPERatio.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.